Allergy Therapeutics (AGY) has issued a trading update for its year ended 30th June 2022 emphasising “effective cost controls implemented alongside the group's significant clinical progress” and “in 2023, sales are expected to return to their previous near double-digit growth levels”. So what of a current share price response to 17p, approaching 7% lower?
Hello Share Puzzlers. Thank goodness the hay fever season is over. I no longer suffer, having moved to the seaside, but the horror of a blocked conk and streaming eyes remains. You may have noticed that allergies seem to be on the rise. At least the number of folk who complain about them is.
It would appear to be that as far as shares of Allergy Therapeutics (AGY) are concerned you do not have to be an expert either on allergies or therapeutics in order to gain exposure to the long side. The movement of the share price is pretty categorical.
If you want me to analyse a stock for you just drop me a line at firstname.lastname@example.org - Today I look at shares of Allergy Therapeutics (AGY), Mercom Oil Sands (MMO), Tiziana Life Sciences (TILS) and offer some share price targets.
We have a slightly unusual set up on the daily chart of Allergy Therapeutics (AGY) currently in the sense that the extended basing that the stock has delivered since the turn of the year offered decent range trades within it.